This Year, the United European Gastroenterology Week (UEGW) took place from 3rd to 5th October 2021. For the second time it was held fully virtual due to the SARS-CoV-2 pandemic. Nevertheless, 8675 people from 116 countries registered for this virtual event, where 2357 abstracts were submitted and 1661 abstracts were presented in more than 215 live streamed sessions, over 770 recordings and more than 1400 e-posters.
For the treatment of different chronic inflammatory diseases such as Inflammatory Bowel Disease (IBD), optimal therapeutic drug levels are key for a successful therapy and therefore require monitoring (TDM). BÜHLMANN offers with the Quantum Blue® Infliximab and Quantum Blue® Adalimumab rapid tests to measure trough levels of infliximab and adalimumab. These tests allow for quick decision making and optimization of patient treatment.
At this Year’s UEGW, BÜHLMANN presented new data:
We demonstrated in an electronic poster and a video presentation, that not only the originator drugs, but also the serum levels of the infliximab biosimilar GP1111 as well as the adalimumab biosimilar adalimumab-adaz from Sandoz were equivalently measured by the Quantum Blue® Infliximab and Quantum Blue® Adalimumab, respectively. Therefore, these rapid tests offer quantification of infliximab and adalimumab originator drugs, as well as their biosimilars GP1111, SB2, CT-P13 and adalimumab-adaz allowing for identification of patients with suboptimal drug levels as part of their therapeutic drug monitoring.